Non-Registered Director Han Myeong-sik Acquires 750 Shares via Stock Purchase Rights... Small but Positive Signal with Below-Market Price


  • [Event] Non-registered director Han Myeong-sik exercised stock purchase rights on May 20, 2026, acquiring 750 additional common shares, increasing his holdings from 1,000 to 1,750 shares.
  • [Reason] The exercise of stock purchase rights indicates the director exercised granted stock options. The acquisition price of KRW 20,000 is approximately 59% lower than the current market price of KRW 48,450.
  • [Impact] This acquisition increased Han's stake by 0.01 percentage point to 0.02%. Although small, insider buying at a discount is a positive signal that management views the current stock price as undervalued.
  • [AI Comprehensive Analysis]The direct market impact is limited due to the small scale, but the insider's low-price acquisition demonstrates confidence in shareholder value enhancement. However, without accompanying share buybacks or dividend increases, the effect on stock price is expected to be negligible.

KOSDAQ Filing Information


  • Filing: Report on Ownership of Specific Securities by Executives and Major Shareholders
  • Company: NEXTBIOMEDICAL (389650)
  • Submission: Han Myeong-sik
  • Receipt: 05-26-2026